GlassScriptPhysician profile
Laure Darcy Pierre
NPI 1588269914
$8,487.70
in general payments reported to CMS, 2019-2025
44 companies · $4,086 in 2025
The $4,086 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.80 · 2022: $409 · 2023: $1,959 · 2024: $1,980 · 2025: $4,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,869 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,869.49 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,598.61 | 2022-2025 | Lynparza, Enhertu, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $980.16 | 2022-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $863.46 | 2023-2025 | |
| Janssen Biotech, INC. | $753.54 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Merck Sharp & Dohme LLC | $709.79 | 2022-2025 | Keytruda, Lynparza, Prevymis |
| Daiichi Sankyo INC. | $584.53 | 2022-2025 | Datroway, Enhertu, Injectafer |
| Jazz Pharmaceuticals INC. | $423.50 | 2025 | |
| Taiho Oncology, INC. | $252.62 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.16 | 2023-2025 | |
| Eisai INC. | $212.48 | 2022-2025 | |
| Amgen INC. | $191.33 | 2022-2025 | Imdelltra (Amg757), Lumakras, Xgeva |
| Immunocore Limited | $154.55 | 2022-2025 | Kimmtrak |
| Takeda Pharmaceuticals U.S.A., INC. | $145.07 | 2022-2025 | Alunbrig, Fruzaqla |
| Pharmaessentia USA Corporation | $141.24 | 2025 | Besremi |
| Abbvie INC. | $128.62 | 2023-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $116.67 | 2024 | |
| Incyte Corporation | $102.30 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Pharmacosmos Therapeutics INC. | $100.89 | 2024-2025 | Cosela, Monoferric |
| Agios Pharmaceuticals, INC. | $88.18 | 2024-2025 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $78.00 | 2025 | Opdivo |
| Genentech USA, INC. | $67.10 | 2024-2025 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Emd Serono, INC. | $65.41 | 2024-2025 | |
| Cumberland Pharmaceuticals, INC. | $55.24 | 2025 | Sancuso |
| Lilly USA, LLC | $46.68 | 2021-2023 | Retevmo, Jaypirca |
| Pfizer INC. | $44.98 | 2022-2023 | |
| Genzyme Corporation | $37.92 | 2021-2025 | |
| Blueprint Medicines Corporation | $34.47 | 2023-2024 | Ayvakit |
| Array Biopharma INC | $22.48 | 2025 | Tukysa, Mektovi, Braftovi |
| Stemline Therapeutics INC. | $20.75 | 2023 | Orserdu |
| Foundation Medicine, INC. | $19.71 | 2022 | |
| Novocure INC. | $19.42 | 2025 | Optune Lua (Novottf-200t) |
| Geron Corporation | $19.00 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $18.80 | 2025 | |
| G1 Therapeutics, INC. | $18.20 | 2023 | Cosela |
| Janssen Scientific Affairs, LLC | $17.82 | 2024 | Erleada |
| Alexion Pharmaceuticals, INC. | $17.18 | 2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $17.00 | 2024 | Onivyde, Somatuline Depot |
| Apellis Pharmaceuticals, INC. | $15.20 | 2024 | Empaveli |
| Deciphera Pharmaceuticals INC. | $15.10 | 2024 | Qinlock |
| Seagen INC. | $15.00 | 2021 | |
| Karyopharm Therapeutics INC. | $14.69 | 2024 | Xpovio |
| Global Blood Therapeutics, INC. | $12.65 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $12.12 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laure Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.